Ticker

NVS

NOVARTIS

13 catalysts on file

NVS

NOVARTIS

Approval Confirmed

Rhapsido

370d ago Sep 30, 2025

openFDA verified 3mo ago

Countdown card →

NVS

Novartis AG

Phase 3 AI-extracted

del-brax

f acioscapulohumeral muscular dystrophy (FSHD)

97d ago Jun 30, 2026

SEC 6-K verified 3mo ago

Countdown card →

NVS

Novartis

Approval Confirmed

Itvisma

spinal muscular atrophy (SMA)

95d ago Jul 2, 2026

Press release verified 3mo ago

Countdown card →

NVS

Novartis Pharmaceuticals

Phase 3 Estimated

LOU064 (blinded)

Chronic Spontaneous Urticaria

T-minus 32 days Nov 6, 2026

ClinicalTrials.gov verified 3mo ago

Countdown card →

NVS

Novartis

Phase 1 AI-extracted

Itvisma

spinal muscular atrophy (SMA)

Date TBD Date TBD

Press release verified 3mo ago

Countdown card →

NVS

Novartis AG

Phase 2 AI-extracted

del-brax

f acioscapulohumeral muscular dystrophy (FSHD)

Date TBD Date TBD

SEC 6-K verified 3mo ago

Countdown card →

NVS

Novartis AG

Approval AI-extracted

del-brax

f acioscapulohumeral muscular dystrophy (FSHD)

Date TBD Date TBD

SEC 6-K verified 3mo ago

Countdown card →

NVS

Novartis AG

AdCom Confirmed

remibrutinib

chronic spontaneous urticaria (CSU)

Date TBD Date TBD

SEC 6-K verified 3mo ago

Countdown card →

NVS

Novartis AG

AdCom Confirmed

ianalumab

Sjögren’s disease

Date TBD Date TBD

SEC 6-K verified 3mo ago

Countdown card →

NVS

Novartis AG

Approval Confirmed

cosentyx

hidradenitis suppurativa (HS) in pediatric patients

Date TBD Date TBD

SEC 6-K verified 3mo ago

Countdown card →

NVS

Novartis AG

Phase 3 Confirmed

ianalumab

Sjögren’s disease

Date TBD Date TBD

SEC 6-K verified 3mo ago

Countdown card →

NVS

Novartis AG

Phase 3 Confirmed

remibrutinib

chronic inducible urticaria

Date TBD Date TBD

SEC 6-K verified 3mo ago

Countdown card →

NVS

Novartis AG

Phase 2 Confirmed

remibrutinib

food allergy

Date TBD Date TBD

SEC 6-K verified 3mo ago

Countdown card →